Randomized trial of two schedules of low-dose gemtuzumab ozogamicin as induction monotherapy for newly diagnosed acute myeloid leukaemia in older patients not considered candidates for intensive chemotherapy. A phase II study of the EORTC and GIMEMA leukaemia groups (AML-19)

✍ Scribed by Sergio Amadori; Stefan Suciu; Dominik Selleslag; Roberto Stasi; Giuliana Alimena; Liliana Baila; Vittorio Rizzoli; Erika Borlenghi; Gianluca Gaidano; Domenico Magro; Giuseppe Torelli; Petra Muus; Adriano Venditti; Emma Cacciola; Francesco Lauria; Marco Vignetti; Theo De Witte

• Book ID: 108676691
• Publisher: John Wiley and Sons
• Year: 2010
• Tongue: English
• Weight: 119 KB
• Volume: 149
• Category: Article
• ISSN: 0007-1048
• DOI: 10.1111/j.1365-2141.2010.08095.x